CRISPR Therapeutics AG (CRSP) Operating Margin: 2015-2025
Historic Operating Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -14,854.78%.
- CRISPR Therapeutics AG's Operating Margin rose 343924.00% to -14,854.78% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,498.28%, marking a year-over-year decrease of 133440.00%. This contributed to the annual value of -1,250.38% for FY2024, which is 119043.00% down from last year.
- Latest data reveals that CRISPR Therapeutics AG reported Operating Margin of -14,854.78% as of Q3 2025, which was up 42.22% from -25,708.97% recorded in Q2 2025.
- In the past 5 years, CRISPR Therapeutics AG's Operating Margin registered a high of 84.67% during Q2 2021, and its lowest value of -2,192,350.00% during Q4 2022.
- Its 3-year average for Operating Margin is -13,351.50%, with a median of -16,006.81% in 2025.
- Its Operating Margin has fluctuated over the past 5 years, first plummeted by 219,122,047bps in 2022, then spiked by 219,238,458bps in 2023.
- Over the past 5 years, CRISPR Therapeutics AG's Operating Margin (Quarterly) stood at -1,129.53% in 2021, then crashed by 219,122,047bps to -2,192,350.00% in 2022, then surged by 219,238,458bps to 34.58% in 2023, then tumbled by 21,555bps to -180.96% in 2024, then spiked by 343,924bps to -14,854.78% in 2025.
- Its Operating Margin was -14,854.78% in Q3 2025, compared to -25,708.97% in Q2 2025 and -17,158.84% in Q1 2025.